Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis
Clinical Transplantation and Research · 2024
DOI: 10.4285/ctr.24.0015 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Clinical Transplantation and Research, 2024. Verfasst von Saeed Khorramnia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Tixagevimab/cilgavimab (Tix/Cil) shows promise as a prophylactic treatment against coronavirus disease 2019 (COVID-19) in solid organ transplant recipients (SOTRs). This study was performed to assess the effectiveness of Tix/Cil for preexposure prophylaxis against COVID-19 in this population.
Methods
We systematically searched the Cochrane Library, Web of Science, PubMed, and Embase databases to identify articles relevant to our study up to December 15, 2023. Comprehensive Meta-Analysis (ver. 3.0) was used for data analysis.
Results
The meta-analysis included seven eligible retrospective studies, encompassing a total of 4,026 SOTRs. The analysis revealed significant differences in SOTRs who received Tix/Cil preexposure prophylaxis relative to those who did not. Specifically, these differences were observed in the incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (odds ratio [OR], 0.30; 95% confidence interval [CI], 0.15-0.60), hospitalization (OR, 0.24; 95% CI, 0.08-0.70), and intensive care unit admission (OR, 0.07; 95% CI, 0.02-0.22). However, mortality rate did not differ significantly between the two groups (P=0.06).
Conclusions
The evidence supporting the effectiveness of Tix/Cil as preexposure prophylaxis against SARS-CoV-2 in SOTRs is of a low to moderate level. Further high-quality research is necessary to understand its effects on this population.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anesthesiology, School of Medicine, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
- Department of Anesthesiology, School of Medicine, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran.
- Department of Anesthesiology, Paramedical Faculty, Hajar Hospital, AJA University of Medical Sciences, Tehran, Iran.
- Department of Anesthesia and Critical Care, Sina Hospital, Tehran University of Medical Sciences, Tehran, Iran.
- School of Nursing, AJA University of Medical Sciences, Tehran, Iran.
ORCID-Profile: Saeed Khorramnia, Zia Navidi, Amirhossein Orandi, Mojgan Mohajeri Iravani, Amirali Orandi, Ebadallah Shiri Malekabad, Seyed Hamid Pakzad Moghadam
Zitieren
APA
Khorramnia, S., Navidi, Z., Orandi, A., Iravani, M. M., Orandi, A., Malekabad, E. S., & Moghadam, S. H. P. (2024). Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis. Clinical Transplantation and Research. https://doi.org/10.4285/ctr.24.0015
Vancouver
Khorramnia S, Navidi Z, Orandi A, Iravani MM, Orandi A, Malekabad ES, et al. Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis. Clinical Transplantation and Research. 2024. doi:10.4285/ctr.24.0015
BibTeX
@article{Khorramnia2024,
author = {Khorramnia, Saeed and Navidi, Zia and Orandi, Amirhossein and Iravani, Mojgan Mohajeri and Orandi, Amirali and Malekabad, Ebadallah Shiri and Moghadam, Seyed Hamid Pakzad},
title = {Tixagevimab/cilgavimab prophylaxis against COVID-19 in solid organ transplant recipients: a systematic review and meta-analysis},
journal = {Clinical Transplantation and Research},
year = {2024},
doi = {10.4285/ctr.24.0015}
}
EUVIMED